Binding and functional comparisons of two types of tumor necrosis factor antagonists.

By B. Scallon, Ann Cai, Nancy L. Solowski, A. Rosenberg, Xiao-yu Song, D. Shealy, C. Wagner. Journal of Pharmacology and Experimental Therapeutics, 2002

722 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging, Rheumatology

View Paper: https://www.semanticscholar.org/paper/274d11264f8cb7ba733c3e39aea73dc0602cee9a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Rheumatology

1. D. Tracey
2. Lars Klareskog
3. J. Salfeld
4. P. Tak
5. E. Sasso

Citations in the corpus

• Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. (2008, background): “In contrast to the anti-TNF mAbs, which have the potential to crosslink 2 tmTNF trimers, it appears that etanercept preferentially binds with both receptor arms to a single tmTNF trimer, with little or no potential to crosslink 1 tmTNF trimer to another (Scallon et al., 2002).”
• TNF‐mediated inflammatory disease (2008, background): “Infliximab binds transmembrane TNF with higher avidity, forming more stable complexes and more effectively inhibiting the actions of transmembrane TNF than entarecept [81].”
• Granulomatous infectious diseases associated with tumor necrosis factor antagonists. (2004, result): “However, the in vitro data often describe conflicting results [23–25].”